Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear MedicineResearch in Oncology2357-068712220161201Outcome of Patients with Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: Egyptian Experience3339253710.21608/resoncol.2017.615.1014ENSalah ElmesidyDepartment of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptHussam ZawamDepartment of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt0000-0001-9921-9560Asmaa HassanDepartment of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptMohamed Abol-KasemDepartment of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptRadwa FawzyDepartment of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptMahmoud AbdelsalamDepartment of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptJournal Article20170128Background: Lung cancer remains the most common primary tumor responsible for brain metastases making up to 40% to 50% of cases. Brain metastases from NSCLC is associated with poor prognosis. <br /> Aim: The aim of this study is to analyze the risk factors and treatment outcome of patients with NSCLC who developed brain metastases; and to identify which subgroup of these patients is associated with better survival outcome.<br /> Methods: We analyzed all patients with NSCLC presented to Kasralainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) during the period between January 2006 and December 2012. Seven hundred and fourteen patients were found, from which 132 had clinical evidence of brain metastases.<br /> Results: The median time to development of brain metastases (TTBM) was 6 months. Factors associated with longer TTBM were good PS (1-2) (P=0.004), early stages at presentation (stage I&II) (P<0.0001) and administration of chemotherapy (P<0.0001). Median overall survival from the time of development of brain metastases was 5 months. Factors associated with longer OS were; good PS (1&2) at development of brain metastases (P<0.0001), controlled lung primary (P<0.0001), absence of extracranial metastases (P=0.019), the use of chemotherapy after development of brain metastases (P<0.0001) and whole brain irradiation (P=0.001). Controlled lung primary and administration of chemotherapy were independent prognostic factors associated with higher OS (P= 0.006 and 0.02 respectively).<br /> Conclusion: After development of brain metastases; patients with good PS(1-2), controlled lung primary and absence of extracranial metastases are associated with better outcome than other cases.https://resoncol.journals.ekb.eg/article_2537_696323f8a97bbcd3ae68dce38faeea96.pdfCairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear MedicineResearch in Oncology2357-068712220161201A Prospective Study of Adjuvant Radiotherapy Concomitant with Cisplatin Followed by Paclitaxel-Carboplatin in High Risk Early Stage Endometrial Cancer4046254010.21608/resoncol.2017.234.1010ENTarek KamelDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, EgyptWalid BayoumyDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, EgyptMohamed Al-KadyDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, EgyptMohamed MustafaDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, EgyptCaroline El-MaraghiDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, EgyptJournal Article20160930Abstract:<br /> Purpose: To study the efficacy and toxicity of adjuvant radiotherapy concomitant with cisplatin followed by paclitaxel, carboplatin in high risk early stage endometrial cancer.<br /> Patient and methods: Patients with higher risk endometrial cancer defined in this study as those having > 50% myometrial invasion or grade 3 or lymphovascular invasion positive or those stage II, IIIA, or finally those with clear cell or papillary serous histology whatever the stage were enrolled post total abdominal hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy. Patients received adjuvant pelvic external beam (RTH) (46.8-50.4 Gy) concomitant with cisplatin (50 mg/m2) every 21 days followed by 4 cycles of paclitaxel 175 mg/m2 carboplatin (AUC5) every 21 days. Primary end point was disease free survival and the secondary end point were tolerability and toxicity.<br /> Results<br /> 21 patients from clinical Oncology Department, Ain Shams University from June 2013-March 2016 were enrolled. The median follow up time was 21 months (range from 9—33 months). 19 patients (90.41%) completed the RTH and the 4 cycles of adjuvant CTH. Overall grade 3-4 hematological toxicity was 23.8%, it was mainly neutropenia. Grade 3-4 non hematological toxicity was seen in 3 patients (14.28%), 2 patients had grade 3 neuropathy and a third patient experienced grade 3 diarrhea with the chemotherapy. Disease recurrence was registered in 3/21 patients (14.28%). The <br /> 1 and 2 years DFS were 93.8% and 73.8% respectively.<br /> Conclusion:<br /> Adjuvant sequential RTH followed by paclitaxel, carboplatin is well tolerated and feasible regimen in patients with higher risk EC.https://resoncol.journals.ekb.eg/article_2540_eeb0bfc1480290acfcc316e0de17ba26.pdfCairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear MedicineResearch in Oncology2357-068712220161201Effect of Chemotherapy on the Nutritional Status of Egyptian Patients with Breast Cancer4753257010.21608/resoncol.2017.656.1016ENSoha TalimaClinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptLamia NabilMedical Surgical Department, Faculty of Nursing, Cairo University, Cairo, EgyptMahmoud El-MeghawryMedical Surgical Department, Faculty of Nursing, Cairo University, Cairo, EgyptJournal Article20170427Background: Chemotherapy and chemotherapy-related symptoms may greatly affect the nutritional status of the patient and reduces the quality of life. Aim of the study: Assessment of the effect of chemotherapy on the nutritional status of breast cancer patients. Methods: In this prospective observational study, we assessed the nutritional status of 60 breast cancer patients receiving chemotherapy by anthropometric measurements including body weight (BW), body mass index (BMI), triceps skin fold (TSF), and mid arm muscle circumference (MAMC). Symptoms related to chemotherapy were<br />assessed with a yes/no questionnaire. Results: Forty three patients (71%) experienced weight loss during the course of treatment. Compared to baseline assessment before starting chemotherapy, there was a significant reduction in the average of all parameters at the end of chemotherapy. Body weight decreased from 78.97 (±9.6) kg to 73.65 (±14.1) kg, BMI from 30.15 (±3.2) kg/m2 to 28.01 (±4.8) kg/m2, TSF from 4.23 (±0.5) cm to 3.97 (±0.68) cm and MAMC from 36.31 (4.02) cm to 34.61 (±5.04) cm (p < 0.001 for all). Significant reduction in BMI observed in patients who experienced alteration in taste especially those with taste alteration for > 1 week (p < 0.001). Similarly, BMI reduction was significantly associated with loss of appetite and its duration (p < 0.001). Conclusion: During chemotherapy, breast cancer patients are prone to lose weight particularly, those patients who experience taste alteration and appetite-loss for longer duration https://resoncol.journals.ekb.eg/article_2570_68b682e7310764f1f76d11685e1a7649.pdfCairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear MedicineResearch in Oncology2357-068712220161201Effect of Body Mass Index on Survival in Patients with Epithelial Ovarian Cancer5459257710.21608/resoncol.2017.223.1007ENSuzy GoharDepartment of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin Elkom, Egypt0000-0003-3250-5954Ashraf Abdel-GhanyDepartment of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin Elkom, EgyptShaimaa SolimanDepartment of Public Health and Community Medicine, Faculty of Medicine, Menoufia University, Shibin Elkom, EgyptJournal Article20170427Introduction: Higher body mass index (BMI) is an independent and well-established prognostic factor in hormonerelated<br />cancers, such as breast and endometrial cancer. As a hormone-dependent cancer, ovarian cancer, however, has been linked inconsistently to obesity. Aim: This work aimed to assess the association between BMI and ovarian cancer survival.<br />Methods: This retrospective study included 66 patients who were treated for epithelial ovarian cancer from January 2011<br />to April 2014. Clinical and epidemiological characteristics of patients were collected. Time to progression and overall survival were calculated. BMI was calculated using the formula weight in kilograms divided by the square of the height in meters, and categorized according to World Health Organization classification.Results: BMI indicated underweight in 3 patients (4.5%), healthy weight range in11 (16.7%), pre-obesity in 17 (25.8%),obesity class I in 13 (19.7%), obesity class II in 8 (12.1%) and obesity class III in 14 (21.2%). BMI did not associate significantly with disease stage (p=0.54), pathology (p=0.82), initial CA-125 level (p=0.61), platinum sensitivity(p=0.27), time to progression (p=0.58) or overall survival (p=0.87).Conclusion: Our results suggest prevalence of obesity (relatively high) among Egyptian patients with epithelial ovarian cancer. Noteworthy, BMI had no significant association with disease stage, platinum sensitivity, time-to-progression or overall survival in the studied group.https://resoncol.journals.ekb.eg/article_2577_03bb88f2a22821fadfeadfd867cef450.pdfCairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear MedicineResearch in Oncology2357-068712220161201Awareness of Diagnosis in Patients with Cancer: A Study from Egypt6063258510.21608/resoncol.2016.332.1011ENAhmad HammadPalliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptDina FaragPalliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptMostafa El-HaddadClinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptRasha HaggagMedical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, EgyptOmar ZakiClinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptNoha IbrahimClinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EgyptSamy AlsirafyPalliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt0000-0003-4282-6671Journal Article20170427Background: One of the barriers to cancer care is the inadequate communication with patients and their families. In<br />Egypt, it is believed that culture is against the honest disclosure of cancer diagnosis. So, the majority of cancer patients<br />are usually unaware of their diagnosis.Aim: To study cancer diagnosis awareness among a group of Egyptian patients and the factors contributing to their unawareness. Methods: The study included 119 cancer patients from two cancer centers; one in Cairo and the other in Sharkia. Patients were asked about their illness and who answered as having cancer/tumor” or mentioned the name of cancer considered aware. Results: The majority of our patients (100/119, 84%) were aware of their cancer diagnosis. Their answer was “cancer” in 31%, “tumor” in 60% and the name of cancer in 9%. While, a nority (19 /119, 16%), were unaware of their cancer diagnosis. They were more likely to be less educated, older in age, males, unmarried, and from Sharkia. None of the studied variables associated significantly with awareness. Conclusions: The results of this study suggest that most cancer patients in Egypt are aware of their diagnosis. This may be due to a change in the Egyptian cultural attitude towards truth telling and a shift in the approach of care from paternalistic to patient-centred.https://resoncol.journals.ekb.eg/article_2585_984da33d1f33c927ac2e205efc0155cf.pdf